Search Results - "Reboredo-Rendo, C."

A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

Authors: Garrigós, L. Ruiz-Borrego, M. Pérez-García, J.M. et al.

Source: Annals of Oncology. Jun2026, Vol. 37 Issue 6, p837-848. 12p.

460eTiP TELESCOPE: Neoadjuvant phase II study of pembrolizumab, carboplatin, and paclitaxel for stage I triple-negative breast cancer.

Authors: Gion, M. Llombart Cussac, A. Perez Garcia, J.M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS390-S391. 2p.

301P HER2DX in the modulation of HER2-positive early breast cancer (HER2+ eBC): A retrospective analysis.

Authors: Alonso de Castro, B. Cobo, S. Perez MaLillyos, J. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS327-S328. 2p.

P-175 Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors.

Authors: Gomez-Randulfe Rodriguez, M. Alonso de Castro, B. Castro Lopez, E. et al.

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS159-S160. 2p.

P-31 Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies.

Authors: Martínez Lago, N. Alonso de Castro, B. Varela Ponte, R. et al.

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS106-S107. 2p.

P-157 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen.

Authors: Martínez-Lago, N. Carmona Campos, M. Gonzalez Villarroel, P. et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv42-iv43. 2p.

P-34 Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors.

Authors: Martínez Lago, N. Cousillas Castiñeiras, A. Fernández Montes, A. et al.

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS107-S107. 1p.